Pasteur Institute of Algeria Strengthens Health Security Through Modernization and Local Vaccine Production
The Pasteur Institute of Algeria has undergone significant transformations in recent years, particularly in response to the COVID-19 pandemic, bolstering Algeria’s preparedness for future health emergencies. These advancements include strengthened scientific research, expanded research projects, and initiatives to locally produce vaccines and serums.
Strategic Role in Algeria’s National Health System
The Pasteur Institute of Algeria serves as a crucial reference center within the national health system, offering a wide range of scientific specializations in virology, immunology, bacteriology, and animal medicine. It has similarly expanded into advanced cancer research, focusing on early diagnosis and genetic tracking of tumors. The institute is uniquely authorized to procure vaccines, particularly for the National Child Vaccination Program and influenza vaccines.
Impact of the COVID-19 Pandemic and Digital Transformation
During the COVID-19 pandemic, the Pasteur Institute was responsible for diagnosing the epidemic nationwide and initiated research to support the development of national vaccine capabilities. Researchers were deployed across the country to establish a laboratory system for virus diagnosis, which also enhanced the capacity to diagnose other diseases. Following the pandemic, the institute invested in the latest technological devices and digitized 90% of its activities, improving research and medical file management.
Local Vaccine and Serum Production
The institute is actively developing programs to produce serums locally, with a production plant expected to be operational by 2027. This will enable Algeria to meet national and regional demand for anti-rabies, diphtheria, and tetanus serums, as well as produce vaccines for research and development purposes. Collaboration with Sidal is underway, and partnerships with African countries through the African Vaccination Initiative, supervised by the Pasteur Institute in Senegal, aim to establish a joint African infrastructure for vaccine production and distribution.
Epidemiological Situation and Current Viral Threats
While Algeria is not immune to epidemic waves, the Pasteur Institute monitors potential threats, such as West Nile fever detected in the south and east of the country. The current epidemiological situation is stable, with a seasonal viral wave observed in January 2026. While COVID-19 cases declined in late December 2025, the H3N2 strain of influenza emerged as a significant concern, causing serious health complications in some cases. A national vaccination campaign, with two million doses of influenza vaccine acquired by the Pasteur Institute, proved successful in forming collective immunity and reducing pressure on emergency departments and hospitals.
Pilgrim Vaccination Program
The Institute has provided over 50,000 doses of vaccine for pilgrims, distributed through designated vaccination centers. Meningitis vaccines are also provided to pilgrims during Ramadan.
International Partnerships and Health Security
The Pasteur Institute of Algeria maintains strong partnerships with the Pasteur Institute network globally, collaborating on research projects in areas such as leishmania treatment (with Tunisia), water-borne diseases (with Senegal), and respiratory viruses (with Saudi Arabia). These collaborations, along with Algeria’s pharmaceutical self-sufficiency, contribute to national and regional health security. Algeria’s experience and independent health system position it as a potential provider of expertise and aid to other countries.
Looking Ahead
The Pasteur Institute of Algeria continues to strengthen its role in safeguarding public health through ongoing research, modernization, and strategic partnerships. By prioritizing local vaccine production and maintaining a vigilant approach to emerging health threats, the institute is well-positioned to address future challenges and enhance health security for Algeria and the region.